Member Info for Diversified

I have had no reply from investor relations. Either investor relation department is terrible or news is imminent!

Further signs of the company ramping up in anticipation of results. A further indication of a positive outcome imo as you wouldn’t be increasing your cost base if results were to be unsuccessful.

Great finish is the US and after hours.

New website up and running today and we know the Phase II results are imminent. Looks like the party is about to begin.

Agreed. When you consider what happened to the share price when the last drilling campaign and CPR were announced (40 up to 100p) and now we have two oil discoveries in our pocket and a proven petroleum system in our basin. Fully funded for the upcoming campaign in the hottest exploration area in the world with short term catalysts to boot.

Undervalued is an understatement!

https://oilnow.gy/featured/eco-atlantic-sees-significant-thick-oil-pay-opportunities-at-orinduik-following-carapa-results/

L2 just got interesting

Any significant update is likely to come at 13:00 rather than 07:00 due to Nasdaq listing as and when they decide to update.

Any significant update is likely to come at 13:00 rather than 07:00 due to Nasdaq listing as and when they decide to update.

Novartis Pharma is the most exciting shareholder. They recognise the value of the drugs that this company is developing

Look at yesterday’s pre market opening on Nasdaq which was Blue and then as soon as the market opened it fell hard. Pre and after market opening has no real bearing on the actual closing price.

Very positive movement that should be sustained within a reasonable, i.e. realistic spread.

Happy new year!

Looks like it’s about to take off over the pond!

https://reportofnews.com/2019/12/31/global-upper-respiratory-tract-infection-treatment-outlook-by-product-overview-application-and-regions-2025/

Can’t buy stock right now!

Not unusual at all, 2 PME is more of a rare occurrence than 1

A price monitoring extension is activated when the matching process would have otherwise resulted in an execution price that is a pre-determined percentage above or below the price of the most recent automated execution today. The applicable percentage is set by reference to a security's Millennium Exchange sector

The amount of buys today, you can see how artificial the drop is and the US should be good to watch as it might be the last opportunity to take a position prior to results.

With phase II results imminent it’s hardly a pump and dump, all will be determined by the outcome of those results.

All will be dependent on the 6 month update on the MPH-966 results at year end and any commercial partnerships the company is likely to enter into.

No smoke without fire, Enjoy your weekend

MPH-966 for alpha-1 antitrypsin deficiency (AATD). The Company recently announced dosing of the first patient in a Phase 2 dose ranging study in the U.S. with data expected around the end of 2019

Keeping us on our toes*